Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NCT03417739 · Dana-Farber Cancer Institute · PHASE2 · terminated · last registry update 2026-07-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This was a Simon two stage design trial that terminated after the first stage due to lack of response.” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPK3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2025-09-25Results posted on the registry: BioMed Valley Discoveries, Inc, Ulixertinib + Hydroxychloroquine (NCT05221320)
- 2025-09-25Also stopped (terminated): BioMed Valley Discoveries, Inc, Ulixertinib + Hydroxychloroquine (NCT05221320)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision